Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of cardiotoxicity after neoadjuvant therapy for HER2-negative breast cancer
ChiCTR2100054023Phase 4Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Harbin Medical University
- Start
- Dec 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of epirubicin, doxorubicin, docetaxel and cyclophosphamide in breast cancer, sponsored by The 2nd Affiliated Hospital of Harbin Medical University. Primary endpoints: cardiotoxicity, health-related quality of life score and 5 more. Started Dec 2021; status: recruiting.
02
Drugs
epirubicindoxorubicindocetaxelcyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100054023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054023.